Popis: |
Chung-Hwan Chen,1 Seung-Jae Lim,2 Jong-Keon Oh,3 Tsan-Wen Huang,4 Yuhong H Zeng,5 Meng-Ting Wu,6 Huilin L Yang,7 Jason Pui-Yin Cheung,8 Ji Wan Kim,9 Jeong Hee Han,10 Li Huo,11 Tsung-Jung Lin,12 Gang Zhou,11 Wen-Shuo Wu12 1Department of Orthopedics and Orthopedic Research Center, Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan; 2Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 3Department of Orthopedics, Korea University Guro Hospital, Seoul, South Korea; 4Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan; 5Department of Osteoporosis, Honghui Hospital, Xi ‘an Jiaotong University, Xian, People’s Republic of China; 6Division of Neurosurgery, Department of Surgery, Cheng Hsin General Hospital, Taipei, Taiwan; 7Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 8Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong, People’s Republic of China; 9Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea; 10Department of Medical Quality and Regulatory Affairs, Lilly Korea Ltd., Seoul, South Korea; 11Lilly China Drug Development and Medical Affairs Center, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, People’s Republic of China; 12Department of Medical Affairs, Eli Lilly and Company (Taiwan), Inc., Taipei, TaiwanCorrespondence: Wen-Shuo WuEli Lilly and Company (Taiwan), Inc., 11/F, No. 365 Fu Hsing N. Road, Taipei 105 R.O.C., TaiwanTel +886 2 2715 2950 ext 2234Email wu_marco@lilly.comPurpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia.Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan.Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were − 3.11 (1.54), − 2.58 (1.11), and − 2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥ 2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5L Visual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2).Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.Keywords: postmenopausal osteoporosis, teriparatide, observational study, fractures, East Asia |